Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111057729A details a green enzymatic route for Larotretinib intermediates, offering high ee values and cost reduction in API manufacturing.
Patent CN113061594A reveals novel immobilized transaminase mutants for sitagliptin synthesis, offering superior stability in aqueous isopropanol and reduced manufacturing costs.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Patent CN115725668B reveals high-purity L-vinylglycine via multi-enzyme cascade. Offers supply chain reliability and cost reduction in agrochemical intermediate manufacturing.
Patent CN1993472A details a lipase-catalyzed route for chiral 3-hydroxy acids, offering cost reduction in API manufacturing and superior supply chain reliability.
Patent CN117660389A reveals mutant transaminase for chiral amines. Offers high conversion and purity for pharma and agrochemical manufacturing supply chains.
Patent CN105358687B reveals surface displayed designer cells for efficient chiral alcohol production offering significant supply chain and cost advantages for pharmaceutical manufacturing.
Patent CN1177958A details a lipase-catalyzed resolution of pyrazole carbinols. Discover cost-effective, high-purity manufacturing solutions for analgesic intermediates.
Patent CN112708641A discloses a high-efficiency chemo-enzymatic route for tomoxetine. Achieves >99.9% ee and high substrate loading for cost-effective manufacturing.
Patent CN113801859A details high-efficiency carbonyl reductase mutants for chiral alcohol synthesis, offering superior stereoselectivity and cost reduction in pharmaceutical manufacturing.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN107641622B reveals efficient enzymatic hydrolysis of terephthalonitrile, offering cost reduction in pharmaceutical intermediate manufacturing with high substrate tolerance.
Patent CN107384887A reveals high-purity Sitagliptin synthesis via aminotransferase. Achieves 99% ee and 76% yield, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Novel omega-aminotransferase mutant enables high-yield sitagliptin intermediate production with 99% ee value and reduced solvent constraints for global supply chains.
Patent CN116396950A reveals a novel carboxylesterase mutant for efficient (R)-3-cyclohexene-1-carboxylic acid production, offering superior stereoselectivity and scalable biocatalysis for API intermediates.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediates. Achieves 90% conversion with superior purity and reduced environmental impact for pharma supply chains.
Patent CN118374465B reveals enzymatic route for (S)-nicotine. Achieves 99.1% ee value. Offers scalable biocatalysis for reliable pharmaceutical intermediates supplier chains.
Patent CN105734028A reveals high-efficiency epoxide hydrolase mutants for R-epichlorohydrin production, offering superior stability and supply chain reliability.